In December 2004, GPC Biotech received clearance from Swiss authorities to initiate human clinical testing with the HuCAL®-derived anticancer monoclonal antibody 1D09C3. In total, the clinical trials will involve three different sites in Europe and first commence at the Oncology Institute of Southern Switzerland (IOSI), a world-renowned oncology center that has been involved in numerous previous Phase 1 studies.